Sign Up Today and Learn More About Ultima Genomics Stock
Invest in or calculate the value of your shares in Ultima Genomics or other pre-IPO companies through EquityZen's platform.
Ultima Genomics Stock (ULGE)
Ultima Genomics is a developer of a low-cost sequencing platform.
About Ultima Genomics Stock
Founded
2016
Headquarters
Newark, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.
Ultima Genomics Press Mentions
Stay in the know about the latest news on Ultima Genomics
Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center
biospace • Jun 27, 2025
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
prnewswire • Jun 26, 2025
Proteomics Partnerships Move Multiomics from Theory to Practice
sdbn • Jun 14, 2025
Variability in blood sugar response depends on individual's metabolic health status
news-medical • Jun 09, 2025
Myllia Biotechnology Unveils First-Ever Platform Enabling Genome-Wide CRISPR Screens in Primary Human Macrophages and Dendritic Cells
biospace • Jun 06, 2025
Ultima Genomics Management
Leadership team at Ultima Genomics
CSO
Doron Lipson
Founder & CEO
Gilad Almogy
Join now and verify your accreditation status to gain access to:
- Ultima Genomics Current Valuation
- Ultima Genomics Stock Price
- Ultima Genomics Management
- Available deals in Ultima Genomics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ultima Genomics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ultima Genomics Revenue and Financials
- Ultima Genomics Highlights
- Ultima Genomics Business Model
- Ultima Genomics Risk Factors
- Ultima Genomics Research Report from SACRA Research
Trading Ultima Genomics Stock
How to invest in Ultima Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Ultima Genomics through EquityZen funds. These investments are made available by existing Ultima Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Ultima Genomics stock?
Shareholders can sell their Ultima Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
